Last reviewed 2026-05-14 · How we verify

GSK investigational vaccine 2186877A

GlaxoSmithKline · Phase 3 active Biologic

GSK investigational vaccine 2186877A is a Vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development.

GSK2186877A is an investigational vaccine designed to stimulate immune responses against specific disease targets through immunological priming.

At a glance

Generic name	GSK investigational vaccine 2186877A
Sponsor	GlaxoSmithKline
Drug class	Vaccine
Modality	Biologic
Therapeutic area	Immunology
Phase	Phase 3

Mechanism of action

As a vaccine candidate in Phase 3 development by GlaxoSmithKline, GSK2186877A is engineered to activate the adaptive immune system to recognize and respond to a particular pathogen or disease antigen. The specific mechanism depends on the vaccine platform and target antigen, which are not publicly detailed in available sources for this investigational compound.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GSK investigational vaccine 2186877A CI brief — competitive landscape report
GSK investigational vaccine 2186877A updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI

Frequently asked questions about GSK investigational vaccine 2186877A

What is GSK investigational vaccine 2186877A?

GSK investigational vaccine 2186877A is a Vaccine drug developed by GlaxoSmithKline.

How does GSK investigational vaccine 2186877A work?

GSK2186877A is an investigational vaccine designed to stimulate immune responses against specific disease targets through immunological priming.

Who makes GSK investigational vaccine 2186877A?

GSK investigational vaccine 2186877A is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is GSK investigational vaccine 2186877A in?

GSK investigational vaccine 2186877A belongs to the Vaccine class. See all Vaccine drugs at /class/vaccine.

What development phase is GSK investigational vaccine 2186877A in?

GSK investigational vaccine 2186877A is in Phase 3.

Drug class: All Vaccine drugs
Manufacturer: GlaxoSmithKline — full pipeline
Therapeutic area: All drugs in Immunology
Compare: GSK investigational vaccine 2186877A vs similar drugs
Pricing: GSK investigational vaccine 2186877A cost, discount & access